Bayer Introduces Next-Gen CT Power Injector MEDRAD® Stellant FLEX at CIIE 2023

ShanghaiNovember 4, 2023/PR Newswire/ -- The 6th China International Import Expo (CIIE) is about to open. As an "accelerator" and "incubator" for the introduction and implementation of innovative achievements, the CIIE has always been a showcase for various cutting-edge technologies and innovative products. At this year's CIIE, Bayer's Imaging Diagnostics business will once again rally the call for innovation. With its leading-edge products and continuously enhanced innovation capabilities, it will provide patients with comprehensive solutions from precise diagnosis to precise treatment, supporting the "Healthy China 2030" strategy. Among these are innovative, intelligent imaging diagnostic products and solutions, as well as the next-generation CT high-pressure injection system MEDRAD.^® Stellant FLEX will debut at the CIIE, showcasing "an intelligent future of high-quality and efficient healthcare" to the audience.

MEDRAD® Stellant FLEX to Make Its Debut at the 2023 CIIE.

First Exhibition, First Launch: Precision Treatment Demonstrates Strength

With the release of the "14th Five-Year Plan for National Health Informatization," the construction of national health informatization, innovation-led high-quality development of the health sector has also entered a critical window period. How to promote quality transformation, efficiency transformation, and power transformation in health work through digital, networked, and intelligent transformation has become a new challenge for the industry.

In hospitals, CT scans are the largest focus of radiology examinations and are increasing rapidly in both volume and variety. With the increase in radiology equipment, different scanning devices, examination requirements, and patient information have posed greater challenges for contrast agent injections. How to address personalized needs and apply operations more standardly and safely has become an urgent issue in this field.

Based on the above policies and industry trends, Bayer Imaging Diagnosis will unveil the all-new generation CT high-pressure injection system MEDRAD at the 6th CIIE.^® Stellant FLEX, fully demonstrating its innovative strength in the field of precision treatment.

The All-New CT High-Pressure Injection System MEDRAD® Stellant FLEX

Specifically, in terms of balancing precision and safety, MEDRAD^® Stellant FLEX Optimizes Workflow with Color Beacon Technology for Intuitive Air Residue Detection, Ensuring Patient Safety. Dual-Flow Injection Technology Enables Simultaneous Injection of Contrast Agent and Saline in User-Selected Ratios, Achieving Triphasic Injection Protocols to Enhance Imaging Quality with Precision and Optimization.

In terms of personalization, MEDRAD^® Stellant FLEX Utilizes P3T^®The module can support different clinical application scenarios and implement personalized injection protocols. It not only considers the patient's weight and scan duration but also measures the time to peak based on the individual patient's cardiac function, further refining the injection protocol to ensure the accuracy of the imaging timing, promoting a win-win situation for both efficiency and quality control.

Previously, the high-pressure injector system had always been an "information island" isolated from the radiology department network. As the scale of medical services continues to expand, the need for information upgrades has become more urgent. To address this, Bayer offers patients a comprehensive, one-stop imaging solution. For instance, in collaboration with MEDRAD.^® Stellant FLEX with Certegra^TMThe information management workstation can record up to 63 data items; Radimetrics^TMThe radiology information management platform can intelligently correlate and analyze radiation dose and contrast agent injection processes, providing an overall solution for radiological safety. Together, they complement each other, aiming to bridge the "last mile" of medical imaging informatization.

In China, for China, continuously increasing investment in China

Medical imaging has always been an important tool for precise diagnosis and treatment. The brand-new generation of MEDRAD^® The launch of Stellant FLEX marks a significant step in Bayer's efforts to strengthen its precision treatment strategy. The product has already received approval from the National Medical Products Administration (NMPA) and, after its debut at the CIIE, will be officially launched and exhibited on November 10 at the 31st Chinese Society of Imaging Technology (CSIT) Annual Conference and on November 16 at the 30th Chinese Congress of Radiology (CCR).

"MEDRAD^® "Stellant FLEX will further facilitate fast, accurate, and reliable imaging diagnostics, enabling early detection, early diagnosis, and early treatment, helping clinicians better serve patients and allowing them to recover sooner," said Vivian Hu, General Manager of Bayer’s Radiology Business in China.We look forward to bringing cutting-edge intelligent information to the development of China's imaging diagnostics field, providing medical professionals with standardized, efficient, and imaging homogenization-enhancing products and services, and offering Chinese patients a more personalized, precise, and safer diagnosis and treatment experience. Continuously launching innovative and intelligent imaging diagnostic products not only demonstrates Bayer's determination and capability to promote high-quality development in China's healthcare industry but also reflects Bayer's unwavering commitment and confidence in the Chinese market."

Bayer Imaging Diagnostics Business is committed to providing solutions for imaging diagnostics. In addition to continuously introducing more innovative products and solutions, it leverages China's continuously optimized business environment to enhance local manufacturing capabilities and maintains ongoing investments in China to achieve comprehensive development. Over the past 11 years, Bayer has been the only life sciences company in Beijing with an annual output value exceeding 10 billion RMB each year.

To better serve the Chinese market and provide customers with high-quality imaging diagnostic equipment, Bayer has increased its investment by more than 20 million yuan to upgrade its facilities in preparation for medical device production. In September this year, Bayer's imaging diagnostics medical device plant officially opened within the Bayer Prescription Supply Center in Beijing's Economic-Technological Development Area. This marks that Bayer’s imaging diagnostic equipment will soon be locally produced in China. The four types of products manufactured in the new plant will be used in high-pressure injection systems for imaging diagnostics, improving CT contrast diagnostics across various scenarios.

As one of the core disciplines in early disease detection and precise diagnosis, medical imaging has always played a "pioneering" role, serving as a solid foundation for accurate clinical diagnosis and treatment. Bayer has been contributing to radiology and imaging diagnostics for nearly 100 years. Whether in the past or in the future, Bayer's imaging diagnostics will continue to take a leading role through an innovative product portfolio and service commitments, placing patients at the center, advancing precision treatment, driving industry innovation, and contributing to the development of a Healthy China.

(End)